Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 02:30:02 22/01/2026 am IST			5-day change	1st Jan Change
218.01 ^USD	-0.09%		-0.25%	+5.34%

22/01	Health Care Up After Trump Rescinds Tariff Threats - Health Care Roundup	DJ
22/01	Sector Update: Health Care Stocks Higher Late Afternoon	MT

Health Care Flat on Defensive Demand -- Health Care Roundup

Published on 11/18/2025 at 03:40 am IST

Dow Jones

JOHNSON & JOHNSON

-0.09%

NOVO NORDISK A/S

+3.30%

Health-care companies were more or less flat as traders rotated into sectors less sensitive to economic growth and Federal Reserve policy.

Novo Nordisk slashed prices for its obesity drugs months before an agreement with the Trump administration mandating that it lower its GLP-1 prices takes effect.

Johnson & Johnson agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant's oncology pipeline. It was the latest in a long series of deals in which Big Pharma companies expand their portfolios by snapping up smaller biotech rivals.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

11-17-25 1709ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	JOHNSON & JOHNSON	218.01USD	-0.09%	-0.25%	53TCr
	NOVO NORDISK A/S	386.18DKK	+3.30%	+2.26%	26TCr

Latest news about Johnson & Johnson

22/01	Health Care Up After Trump Rescinds Tariff Threats - Health Care Roundup	DJ
22/01	Sector Update: Health Care Stocks Higher Late Afternoon	MT
22/01	Wall Street jumps on Greenland framework deal	RE
22/01	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
21/01	Sector Update: Health Care	MT
21/01	Top Midday Stories: Trump Says US Doesn't Want to Use Force to Acquire Greenland; Netflix Shares Fall on Low Q1 Guidance	MT
21/01	Wall Street regains momentum as Trump speaks at Davos
21/01	Johnson & Johnson, Q4 2025 Earnings Call, Jan 21, 2026
21/01	Global markets live: Netflix, OpenAI, Nvidia, Meta, Alibaba, Netflix…
21/01	J&J expects to elevate free cash flow generation to about $21 billion in 2026 - conf call	RE
21/01	Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	MT
21/01	When America Starts to Feel Like a Risky Asset
21/01	Wall St set to extend losses, eyes on Trump's speech at Davos	RE
21/01	Sector Update: Health Care	MT
21/01	Johnson & Johnson Issues Upbeat 2026 Sales Outlook; Fourth-Quarter Earnings Meet Street Views	MT
21/01	Johnson & Johnson Reports Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2025	CI
21/01	Genmab Posts Higher Darzalex Net Sales in FY25	MT
21/01	Stocks Down Pre-Bell After Recording Biggest Drop Since October	MT
21/01	Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025	CI
21/01	Johnson & Johnson Provides Sales Guidance for the Full Year of 2026	CI
21/01	Johnson & Johnson's Fiscal Q4 Adjusted Earnings, Sales Rise; Sets Fiscal 2026 Outlook	MT
21/01	J&J CFO says 2026 guidance includes "hundreds of millions of dollars" impact from MFN deal with Trump administration	RE
21/01	Genmab: Darzalex Sales Reach Nearly $14.4 Billion in 2025 (Update)	FW
21/01	Genmab: Darzalex Sales Reach Nearly $14.4 Billion in 2025	FW
21/01	(JNJ) Johnson & Johnson Expects 2026 Adjusted EPS Range $11.43 - $11.63, vs. FactSet Est of $11.48	MT

Chart Johnson & Johnson

Duration

Period

JNJ: Dynamic Chart

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2024, Johnson & Johnson has 64 manufacturing facilities located in the United States (23), North America (7), Europe (21), Africa and Asia/Pacific (13). The United States accounts for 56.6% of net sales.

Employees

1,38,100

Sector

Pharmaceuticals

Calendar

24/02 - Ex-dividend day

More about the company